Christopher Puterman

Skåne University Hospital

Papers

1

Total Citations

6

H-Index

1

About

Christopher Puterman is a clinical researcher whose work centers on improving the accuracy of cancer staging, with a particular focus on prostate cancer imaging. His major contributions lie in evaluating the diagnostic performance of advanced nuclear medicine techniques, specifically [18F]-fluorocholine PET/CT, for detecting lymph node metastases in intermediate and high-risk prostate cancer patients. In his most cited work, a 2021 retrospective study, Puterman rigorously assessed the accuracy of this imaging modality against the gold standard of extended lymph node dissection during robotic-assisted laparoscopic prostatectomy. This study, which has garnered 6 citations, provides critical, real-world data that challenges and refines clinical guidelines, highlighting the limitations of FCH PET/CT in primary staging. By directly comparing imaging results with surgical pathology, Puterman’s research offers actionable insights for urologists and oncologists, helping to prevent both under- and over-treatment. His work is a vital contribution to the ongoing effort to personalize cancer care, ensuring that patients receive the most appropriate and evidence-based staging before definitive treatment.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
A retrospective study assessing the accuracy of [18F]–fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection
6 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Skåne University Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago